Jpmorgan Chase & CO Savara Inc Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SVRA
# of Institutions
144Shares Held
147MCall Options Held
242KPut Options Held
797K-
Nea Management Company, LLC Timonium, MD24.5MShares$90.5 Million9.31% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA14.6MShares$53.9 Million12.01% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$45.7 Million7.46% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.16MShares$30.2 Million1.94% of portfolio
-
Black Rock Inc. New York, NY8.03MShares$29.7 Million0.0% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $422M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.